Patent 9145412 was granted and assigned to Acetylon Pharmaceuticals, Inc. on September, 2015 by the United States Patent and Trademark Office.
Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.